Tag Archives: NASDAQ:CYAD

William Blair Sticks to Their Buy Rating for Celyad (CYAD)

William Blair analyst Raju Prasad maintained a Buy rating on Celyad (CYAD – Research Report) today. The company’s shares closed last Monday at $14.02. Prasad commented: “We view the enhanced product potency and persistence favorably and believe the proof-of-concept preliminary

H.C. Wainwright Reaffirms Their Buy Rating on Celyad (CYAD)

H.C. Wainwright analyst Edward White maintained a Buy rating on Celyad (CYAD – Research Report) today and set a price target of $48. The company’s shares closed last Monday at $12.54, close to its 52-week low of $10.19. White commented:

William Blair Keeps Their Buy Rating on Celyad (CYAD)

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Celyad (CYAD – Research Report). The company’s shares closed last Monday at $12.54, close to its 52-week low of $10.19. Prasad commented: “We believe that

Celyad (CYAD) Receives a Buy from JonesTrading

JonesTrading analyst Soumit Roy reiterated a Buy rating on Celyad (CYAD – Research Report) today and set a price target of $60. The company’s shares opened today at $14.50. Roy said: “Our focus remains on r/r AML, and key data

H.C. Wainwright Keeps a Buy Rating on Celyad (CYAD)

H.C. Wainwright analyst Edward White maintained a Buy rating on Celyad (CYAD – Research Report) today and set a price target of $52. The company’s shares closed yesterday at $19.52. According to TipRanks.com, White is a 5-star analyst with an

Celyad (CYAD) Gets a Buy Rating from William Blair

In a report issued on May 9, Raju Prasad from William Blair maintained a Buy rating on Celyad (CYAD – Research Report). The company’s shares closed on Friday at $19.52. Prasad wrote: “We believe the data update represents an inflection